A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer
Hall, M.R., Dehbi, H.-M., Banerjee, S., Lord, R., Clamp, A., Ledermann, J.A., Nicum, S., Lilleywhite, R., Bowen, R., Michael, A., Feeney, A., Glasspool, R., Hackshaw, A., Rustin, G.Journal:
Gynecologic Oncology
DOI:
10.1016/j.ygyno.2020.09.048
Date:
October, 2020
File:
PDF, 1.17 MB
2020
File converter
More search results
More benefits 
